Attenuation of acute morphine withdrawal in the neonatal rat by the competitive NMDA receptor antagonist LY235959

Neuropsychopharmacology

Volumn 26, Issue 3, 2002, Pages 301-310

  Jones, Kathy L ^a,b   Zhu, Hongbo ^b   Jenab, Shirzad ^a   Du, Ted ^a   Inturrisi, Charles E ^a   Barr, Gordon A ^b,c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

c Fos mRNA; Glutamate; LY235959; Neonatal rat; NMDA receptor antagonist; Ontogeny; Opiate withdrawal; Solution hybridization

Indexed keywords

DECAHYDRO 6 PHOSPHONOMETHYL 3 ISOQUINOLINECARBOXYLIC ACID; MESSENGER RNA; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALTREXONE; PROTEIN C FOS; SODIUM CHLORIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG WITHDRAWAL; HEAD MOVEMENT; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RAT; SOLUTION HYBRIDIZATION; SPINAL CORD; VOCALIZATION; WALKING;

ANALGESICS, OPIOID; ANIMALS; ANIMALS, NEWBORN; BEHAVIOR, ANIMAL; BINDING, COMPETITIVE; BRAIN; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; ISOQUINOLINES; MALE; MORPHINE; PREGNANCY; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; RNA, MESSENGER; SPINAL CORD; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0036179966     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(01)00347-5     Document Type: Article

References (66)

1. Age-related functional changes of the glutamate receptor channels in rat Meynert neurones
2. NMDA EPSCs at glutamatergic synapses in the spinal cord dorsal horn of the postnatal rat
3. Behavioral effects of opiates during development
4. Reinforcing properties of opiates during early development
5. Neonatal withdrawal following pre- and postnatal exposure to methadone in the rat
6. Co-treatment with MK-801 potentiates naloxone-precipitated morphine withdrawal in the isolated spinal cord of the neonatal rat
7. Changes in voltage dependence of NMDA currents during development
8. Acute physical dependence in man: Effects of naloxone after brief morphine exposure
9. Developmental increase in the sensitivity to magnesium of NMDA receptors on CA1 hippocampal pyramidal cells
10. Enhancement of the opiate withdrawal response by antipsychotic drugs in guinea-pigs is not mediated by sigma binding sites
11. Excitatory amino acid receptor antagonists and naloxone-precipitated withdrawal syndrome in morphine-dependent mice
12. Opiate withdrawal in the neonatal rat: Relationship to duration of treatment and naloxone dose
13. Isolation and characterization of the c-fos(rat) cDNA and analysis of post-translational modification in vitro
14. The glutamate receptor ion channels
15. Acute and chronic opiate-regulation of adenylate cyclase in brain: Specific effects in locus coeruleus
16. In vivo studies of the cerebral glutamate receptor/NO/cGMP pathway
17. Developmental biology of inflammatory pain
18. The postnatal development of spinal sensory processing
19. A simple technique for the permanent marking of newborn albino rats
20. Synaptic strengthening through activation of Ca2+-permeable AMPA receptors
21. Acute opioid physical dependence in humans: Effect of varying the morphine-naloxone interval. I
22. Acute opioid physical dependence in postaddict humans: Naloxone dose effects after brief morphine exposure
23. The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction
24. Developmental alterations in NMDA receptor-mediated [Ca2+]i elevation in substantia gelatinosa neurons of neonatal rat spinal cord
25. Preclinical evidence for a role of glutamatergic systems in opioid tolerance and dependence
26. Enhanced LTP in mice deficient in the AMPA receptor GluR2
27. Ontogeny of morphine withdrawal in the rat
28. Opiate withdrawal in the fetal rat: A behavioral profile
29. Synchronized overproduction of AMPA, kainate, and NMDA glutamate receptors during human spinal cord development
30. N-methyl-D-aspartate receptors are transiently expressed in the developing spinal cord ventral horn
31. The competitive alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist LY293558 attenuates and reverses analgesic tolerance to morphine but not to delta or kappa opioids
32. Acute opioid physical dependence in humans: Effect of varying the morphine-naloxone interval II
33. Calcium-permeable AMPA receptors mediate long-term potentiation in interneurons in the amygdala
34. NMDA and opioid receptors: Their interactions in antinociception, tolerance and neuroplasticity
35. Opioid systems and the newborn
36. A comparison between acute and chronic physical dependence in the chronic spinal dog
37. Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions
38. The effects of LY293558, an AMPA receptor antagonist, on acute and chronic morphine dependence
39. [3H]MK-801 binding sites in neonate rat brain
40. Reduced sensitivity of the N-methyl-D-aspartate component of synaptic transmission to magnesium in hippocampal slices from immature rats
41. Molecular and cellular basis of addiction
42. Chronic morphine treatment increases cyclic AMP-dependent protein kinase activity in the rat locus coeruleus
43. Glutamate receptors in the mammalian central nervous system
44. Ca(2+)-permeable AMPA receptors induce phosphorylation of cAMP response element-binding protein through a phosphatidylinositol 3-kinase-dependent stimulation of the mitogen-activated protein kinase signaling cascade in neurons
45. The role of the locus coeruleus and N-methyl-D-aspartic acid (NMDA) and AMPA receptors in opiate withdrawal
46. NMDA antagonists and clonidine block c-fos expression during morphine withdrawal
47. NMDA receptor antagonists suppress behaviors but not norepinephrine turnover or locus coeruleus unit activity induced by opiate withdrawal
48. A selective AMPA antagonist, LY293558, suppresses morphine withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal
49. Transient increase of NMDA-binding sites in human hippocampus during development
50. Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance
51. Developmental maturation of the N-methyl-D-aspartic acid receptor channel complex in postnatal rat brain
52. Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs
53. Comparative effects of NG-monomethyl-L-arginine and MK-801 on the abstinence syndrome in morphine-dependent mice
54. Characterization of neonatal rat fentanyl tolerance and dependence
55. Characterization of neonatal rat morphine tolerance and dependence
56. Transient increased density of NMDA binding sites in the developing rat hippocampus
57. Cellular and molecular mechanisms of opioid tolerance and dependence: Progress and pitfalls
58. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801
59. Opiate tolerance and dependence: Recent findings and synthesis
60. Excitatory amino acids and drugs of abuse: A role for N-methyl-D-aspartate receptors in drug tolerance, sensitization and physical dependence
61. The ontogeny of mu opiate tolerance and dependence in the rat: Antinociceptive and biochemical studies
62. Naltrexone-precipitated morphine withdrawal in infant rat is attenuated by acute administration of NOS inhibitors but not NMDA receptor antagonists
63. Inhibition of morphine withdrawal by the NMDA receptor antagonist MK-801 in rat is age dependent
64. Time course of enkephalin mRNA and peptides in cultured rat adrenal medulla
65. Metrazole induces the sequential activation of c-fos, proenkephalin, and tyrosine hydroxylase gene expression in the rat adrenal gland: Modulation by glucocorticoid and adrenocorticotropic hormone
66. Metrazole induction of c-fos and proenkephalin gene expression in the rat adrenal and hippocampus: Pharmacological characterization